Akosua Mireku's profile photo

Akosua Mireku

Manchester

Healthcare Reporter at Pharmaceutical-Technology.com

I’m a reporter for Pharmaceutical Technology and I write about drug development and issues related to the pharmaceutical space @PharmaTechFocus

Featured in: Favicon pharmaceutical-technology.com Favicon einnews.com Favicon clinicaltrialsarena.com Favicon medicaldevice-network.com Favicon investmentmonitor.ai Favicon msn.com Favicon yahoo.com (+1) Favicon hospitalmanagement.net Favicon cellandgene.com Favicon businessandamerica.com

Articles

  • Pharma’s AI prospects get nudged into the future with EU’s AI act

    2 weeks ago | clinicaltrialsarena.com | Akosua Mireku

    The EU Artificial Intelligence (AI) Act may protect citizens, but some experts in the life sciences industry are worried about the potential challenges it may raise for business. As AI continues to permeate the drug development pathway, major players like Eli Lilly, Sanofi, and BioNTech have incorporated the technology into their development pathways through major deals.

  • Pharma’s AI prospects get nudged into the future with EU’s AI act  - Pharmaceutical Technology

    3 weeks ago | pharmaceutical-technology.com | Akosua Mireku

    Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act. Caption: Experts at the LSX World Congress 2025 discussed the potential challenges and benefits associated with the EU AI Act. Credit: Leestat via Getty Images. The EU Artificial Intelligence (AI) Act may protect citizens, but some experts in the life sciences industry are worried about the potential challenges it may raise for business.

  • Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market

    1 month ago | finance.yahoo.com | Akosua Mireku

    Akosua Mireku Wed, Apr 30, 2025, 3:00 AM 7 min read In This Article: As weight loss drugs boom in popularity, some companies are focusing their sights on therapies for muscle loss prevention, a common side effect of weight loss treatments.

  • Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market

    1 month ago | pharmaceutical-technology.com | Akosua Mireku

    Companies are developing myostatin inhibitors for GLP-1RA- related muscle loss, but some experts doubt their necessity. Companies like Regeneron and Eli Lilly are developing therapies to prevent GLP-1RA related muscle loss. Credit: Yuliia Kaveshnikova via Getty Images. As weight loss drugs boom in popularity, some companies are focusing their sights on therapies for muscle loss prevention, a common side effect of weight loss treatments.

  • UK life sciences venture capital funding lags behind

    2 months ago | pharmaceutical-technology.com | Akosua Mireku

    At the BioTrinity Conference, experts champion government funding programmes to bridge gaps in UK venture capital financing. Carmine Circelli described a growing gap between the British healthcare space and other global markets at the BioTrinity 2025 conference. Credit: Max Zolotukhin via Getty Images.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
55
Tweets
11
DMs Open
No
Akosua Mireku
Akosua Mireku @AkosuaMireku1
18 Mar 24

RT @STiR_Comms: In an exclusive interview with @AkosuaMireku1 at @PharmaTechFocus, @Jaguar_Health CEO Lisa Conte discusses the completion o…

Akosua Mireku
Akosua Mireku @AkosuaMireku1
26 May 23

RT @ManasiVaidya22: Whether Medicare will cover drugs like Eli Lilly's #donanemab, after it showed encouraging results in #Alzheimers, is a…

Akosua Mireku
Akosua Mireku @AkosuaMireku1
5 Apr 23

RT @PharmaTechFocus: Following drug shortages last year, the UK has expanded access to hormone replacement therapies (HRT) and reduced over…